Grace Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2018 | — | $7.2M | $6.4M |
| FY2019 | — | $11.0M | $16.9M |
| FY2020 | — | $13.0M | $14.2M |
| FY2021 | — | $55.7M | $50.9M |
| FY2022 | — | $108.3M | $30.3M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2018 | — | $7.2M | $6.4M |
| FY2019 | — | $11.0M | $16.9M |
| FY2020 | — | $13.0M | $14.2M |
| FY2021 | — | $55.7M | $50.9M |
| FY2022 | — | $108.3M | $30.3M |